MedTrace Logo

To Investigate Blood Lipid Changes and Safety After Litorvazet® Tablets in Dyslipidemia Patients

NCT06866509 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2025-04-17

No results posted yet for this study

Summary

This study aims to investigate the lipid-lowering effects and safety of administering Litorvazet tablets (ezetimibe/atorvastatin) over a 24-week period in patients with dyslipidemia scheduled to receive Litorvazet tablets in a real-world clinical setting.

Conditions

Interventions

DRUG

Litorvazet Tablet 10/10mg

Ezetimibe 10 mg + Atorvastatin 10 mg

DRUG

Litorvazet Tablet10/20mg

Ezetimibe 10 mg + Atorvastatin 20 mg

DRUG

Litorvazet Tablet 10/40mg

Ezetimibe 10 mg + Atorvastatin 40 mg

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • Sung-Mi Park, Dr. · Korea University Anam Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2023-12-31
Completion
2024-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06866509 on ClinicalTrials.gov